Comparative adjuvant trial evaluates Army-developed ALF in HIV vaccine regimens
Criteria published for diagnosing the clinical syndrome of CTE during life
15 March 2021Vulnerable newborns being separated from their mothers in COVID-19 pandemic
15 March 2021Comparative adjuvant trial evaluates Army-developed ALF in HIV vaccine regimens
A new Phase 1 vaccine study began today that will evaluate experimental prime/boost HIV-1 vaccine regimens formulated with combinations of different adjuvants, including one from the Army Liposome Formulation (ALF) family of adjuvants developed by scientists with the U.S. Military HIV Research Program (MHRP) at the Walter Reed Army Institute of Research.
